Sulzer Medica In Talks To Divest Electrophysiology Division By August
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Medica's next-generation Res-Q Micron implantable cardioverter defibrillator system, clinical trials for which will begin later this year, could be a major draw for potential acquirers of the firm's electrophysiology division.